ClinicalTrials.gg
CompletedNCT01766778Updated May 15, 2017Results posted

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

A Phase 4 interventional study of LAF237 (vildagliptin) and Metformin in Type-2 Diabetes Mellitus, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.

Enrollment
69th of 118
117 · median 162
Started
2013
with 8 others
Phase 4
43 of 119
none open now
Registered
93rd of 119
by date
Lead sponsor
47 of 119
Novartis Pharmaceuticals

Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 69th largest by enrollment of the 118 interventional ones that give a count, is one of 9 that started in 2013, is one of 43 in phase 4, and was the 93rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About vildagliptin

Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider initiating Vildagliptin and taking balance between efficacy, compliance, risk factors, convenience and medication cost.

03

Conditions studied

  • Type-2 Diabetes Mellitus

Keywords

  • type-2 diabetes mellitus, inadequately controlled Metformin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Male or Female in age ≥18 at Visit 1
  2. Type 2 diabetes mellitus (T2DM) patients on their maximum tolerated dose of Metformin for more than 3 months
  3. (glycosylated ) at Visit 1 greater than 7.0%
  4. With nearest documented record of HbA1c before Visit 1 greater than 7.0% after patient reached his/her maximum tolerated dose of Metformin

Key Exclusion Criteria:

  1. Patients with hepatic impairment, including patients with a pre-treatment (ALT) or aspartate aminotransferase (AST) > 2.5 X the at Visit 1
  2. Patients with moderate or severe renal impairment or end-stage-renal-disease (ESRD) on haemodialysis at the time of enrolment
  3. Patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption
  4. Pregnant women or breastfeeding women at the time of enrolment
  5. Use of insulin or other oral anti-diabetic drug (OAD) apart from Metformin in the past for T2DM treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Active comparator
    LAF237 (vildagliptin) 50mg once daily (QD)

    Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin

    Drug: LAF237 (vildagliptin) · Drug: Metformin

  • Active comparator
    LAF237 (vildagliptin) 50mg twice daily (BID)

    Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin

    Drug: LAF237 (vildagliptin) · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12

    HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c

    Time frame: Baseline, Month 12 (weeK 52)

Secondary outcomes

  1. Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)

    HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model includes terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by age, pre-existing hypertension and microvascular and macrovascular complications for diabetes mellitus. The variables selected for baseline adjustment were based on the lowest AIC.

    Time frame: Baseline, Month 3, 6, 9 and 12

  2. Change in Fasting Plasma Glucose (FPG) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)

    Blood samples were collected to analyze fasting plasma glucose. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model included terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by pre-existing hypertension. The variable selected for baseline adjustment was based on the lowest AIC.

    Time frame: Baseline, Month 3, 6, 9 and 12

  3. Percentage of Patients Achieving Good Glycemic Control

    Blood samples were collected to analyze HbA1c. Good glycemic control is defined as patient achieving Hb1Ac \< 7.0%. Percentage of patients who achieved HbA1c less than 7.0% at month 3, 6, 9 and 12 were reported for this endpoint.

    Time frame: Month 3, 6, 9, 12

  4. Percentage of Overall Drug Compliance in 12 Months

    The overall drug compliance (%) = (Observed Consumption / Expected Consumption) x 100% Where (Observed Consumption / Expected Consumption) = \[1- (Number of missing tablets from all visits/(sum of Allocated Daily Dosage (in tablets) from all visits × No. of Days between the Date Dispensed and the Date Returned))\]

    Time frame: Month 12

  5. Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability

    This analysis reported percentage patients with adverse events and patient discontinued from the study due to adverse events. Aslo, percentage of patients with serious adverse events and death was reported.

    Time frame: Month 12

07

Results

Posted Apr 10, 2017

Participant flow

Participant flow — Overall Study
MilestoneLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
Started5661
Completed5157
Not completed54
Withdrew: Adverse event44
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryChange of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12

HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c

Time frame:
Baseline, Month 12 (weeK 52)
Reported as:
Mean · percentage of Glycosylated Hemoglobin
Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12
percentage of Glycosylated HemoglobinLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12-0.8 ± 1.01-1.0 ± 1.24
SecondaryChange of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)

HbA1c is an integrated measure of average glucose concentration in plasma in the last 2-3 months. Blood samples were collected to analyze HbA1c. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model includes terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by age, pre-existing hypertension and microvascular and macrovascular complications for diabetes mellitus. The variables selected for baseline adjustment were based on the lowest AIC.

Time frame:
Baseline, Month 3, 6, 9 and 12
Reported as:
Least squares mean · percentage of Glycosylated Hemoglobin
Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)
percentage of Glycosylated HemoglobinLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
3 month from baseline-0.6 ± 0.11-0.9 ± 0.10
6 month from baseline-0.7 ± 0.13-0.9 ± 0.12
9 month from baseline-0.7 ± 0.13-0.7 ± 0.13
12 month from baseline-0.6 ± 0.15-0.6 ± 0.15
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)

Blood samples were collected to analyze fasting plasma glucose. Mixed Model of Repeated Measures (MMRM) was used to analyze this outcome. For the MMRM analysis, the model included terms for treatment, period, treatment-by-period interaction and baseline value, and further adjusted by pre-existing hypertension. The variable selected for baseline adjustment was based on the lowest AIC.

Time frame:
Baseline, Month 3, 6, 9 and 12
Reported as:
Least squares mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 3, 6, 9 and 12 (Based on MMRM Analysis)
mmol/LLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
3 month from baseline-0.9 ± 0.18-1.3 ± 0.16
6 month from baseline-1.2 ± 0.18-0.9 ± 0.17
9 month from baseline-1.1 ± 0.17-1.0 ± 0.16
12 month from baseline-0.9 ± 0.20-0.8 ± 0.20
SecondaryPercentage of Patients Achieving Good Glycemic Control

Blood samples were collected to analyze HbA1c. Good glycemic control is defined as patient achieving Hb1Ac \< 7.0%. Percentage of patients who achieved HbA1c less than 7.0% at month 3, 6, 9 and 12 were reported for this endpoint.

Time frame:
Month 3, 6, 9, 12
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Good Glycemic Control
Percentage of patientsLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
At Month 333.347.5
At Month 639.245.6
At Month 945.147.4
At Month 1249.040.0
SecondaryPercentage of Overall Drug Compliance in 12 Months

The overall drug compliance (%) = (Observed Consumption / Expected Consumption) x 100% Where (Observed Consumption / Expected Consumption) = \[1- (Number of missing tablets from all visits/(sum of Allocated Daily Dosage (in tablets) from all visits × No. of Days between the Date Dispensed and the Date Returned))\]

Time frame:
Month 12
Reported as:
Mean · Percentage of overall drug compliance
Percentage of Overall Drug Compliance in 12 Months
Percentage of overall drug complianceLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
Percentage of Overall Drug Compliance in 12 Months96.90 ± 5.68297.48 ± 6.277
SecondaryNumber of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability

This analysis reported percentage patients with adverse events and patient discontinued from the study due to adverse events. Aslo, percentage of patients with serious adverse events and death was reported.

Time frame:
Month 12
Reported as:
Number · Patients
Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability
PatientsLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
Any adverse events1514
Serious adverse events22
Death00
Patients discontinued due to any AE/SAE44

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LAF237 (Vildagliptin) 50mg Once Daily (QD)—2/56 (3.6%)14/56 (25%)
LAF237 (Vildagliptin) 50mg Twice Daily (BID)—2/61 (3.3%)7/61 (11.5%)
Most frequent serious events
Most frequent serious events
EventLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
DuodenitisGastrointestinal disorders1/560/61
stone impairation over proximal urethraRenal and urinary disorders1/560/61
LeukemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/561/61
Renal failureRenal and urinary disorders0/561/61
Most frequent other events
Most frequent other events
EventLAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)
Upper Respiratory Tract InfectionInfections and infestations8/562/61
Elevated liver function testInvestigations2/562/61
HypokalemiaMetabolism and nutrition disorders2/560/61
DizzinessNervous system disorders2/561/61
CoughRespiratory, thoracic and mediastinal disorders2/562/61
EczemaSkin and subcutaneous tissue disorders2/561/61
TineaInfections and infestations0/562/61
HyperkalemiaMetabolism and nutrition disorders1/562/61

Baseline characteristics

Intent to treat (ITT) included all randomized patients who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)LAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)Total
Mean58 ± 10.359 ± 10.058 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)LAF237 (Vildagliptin) 50mg Once Daily (QD)LAF237 (Vildagliptin) 50mg Twice Daily (BID)Total
Female263157
Male303060
08

Study locations

3 sites
  • Novartis Investigative Site
    Hong Kong SAR, Hong Kong
  • Novartis Investigative Site
    HongKong, Hong Kong
  • Novartis Investigative Site
    Tuen Mun, Hong Kong
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Oct 2015, 29 months.

Results were first posted in Apr 2017, 1 year 5 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 29 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2013
First posted
Jan 11, 2013
StartActual
May 13, 2013
Primary completionActual
Oct 22, 2015
CompletionActual
Oct 22, 2015
Results first posted
Apr 10, 2017
Last update
May 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01766778
Responsible party
Sponsor
First posted
Jan 11, 2013
Start date
May 13, 2013
Primary completion
Oct 22, 2015
Completion
Oct 22, 2015
Results posted
Apr 10, 2017
Last update
May 15, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vildagliptin · Metformin

Start the discussion